Abstract
Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumilast which provides additional clinical benefit either as a single agent or as an additive treatment to long-acting bronchodilators. The second approach involves novel strategies using drugs licensed for other indications, such as statins and macrolides; limited prospective studies on these strategies exist at the moment. A third potential approach involves novel agents whose mechanism of action is closely related to COPD mechanisms and pathophysiology. Such novel treatments are of great interest since they may treat both COPD and co-morbidities. Several novel agents are currently under development and may be of importance in the future.
Keywords: Systemic inflammation, COPD, anti-inflammatory agents, statins, macrolides, phosphodiesterase inhibitors
Current Drug Targets
Title:Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation
Volume: 14 Issue: 2
Author(s): Stelios Loukides, Konstantinos Bartziokas, Jorgen Vestbo and Dave Singh
Affiliation:
Keywords: Systemic inflammation, COPD, anti-inflammatory agents, statins, macrolides, phosphodiesterase inhibitors
Abstract: Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumilast which provides additional clinical benefit either as a single agent or as an additive treatment to long-acting bronchodilators. The second approach involves novel strategies using drugs licensed for other indications, such as statins and macrolides; limited prospective studies on these strategies exist at the moment. A third potential approach involves novel agents whose mechanism of action is closely related to COPD mechanisms and pathophysiology. Such novel treatments are of great interest since they may treat both COPD and co-morbidities. Several novel agents are currently under development and may be of importance in the future.
Export Options
About this article
Cite this article as:
Loukides Stelios, Bartziokas Konstantinos, Vestbo Jorgen and Singh Dave, Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation, Current Drug Targets 2013; 14 (2) . https://dx.doi.org/10.2174/1389450111314020008
DOI https://dx.doi.org/10.2174/1389450111314020008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Historical and Clinical Perspective Endorsing Person-centered Management of Fibromyalgia Syndrome
Current Rheumatology Reviews Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry Omega-6 and Omega-3 Polyunsaturated Fatty Acids and Allergic Diseases in Infancy and Childhood
Current Pharmaceutical Design Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in Asthma Genetics and Antiasthma Therapy
Current Respiratory Medicine Reviews Selected Recent Advances in the Synthesis of Bioactive Compounds Using Olefin Metathesis as a Key Step
Current Organic Chemistry Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Regulatory Role of the α7nAChR in Cancer
Current Drug Targets Human Interleukin-19: Structure, Function and Disease Associations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Serum Trough IgG level and Annual Intravenous Immunoglobulin Dose Are Not Related to Body Size in Patients on Regular Replacement Therapy
Drug Metabolism Letters Oesophagogastric Disconnection: Who, How and When? A Review Article
Current Pediatric Reviews α-Fluorinated Ethers as “Exotic” Entity in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets